CAS 592542-59-1

Rigosertib

Description:

Rigosertib is a small molecule inhibitor primarily known for its role in cancer therapy, particularly in the treatment of myelodysplastic syndromes and other hematological malignancies. It functions by targeting specific signaling pathways, particularly those involving the Ras oncogene, thereby disrupting cell proliferation and promoting apoptosis in cancer cells. Rigosertib is characterized by its ability to inhibit the activity of various kinases, which are crucial for tumor growth and survival. The compound is typically administered intravenously and has been the subject of various clinical trials to evaluate its efficacy and safety profile. Its chemical structure includes a unique arrangement of functional groups that contribute to its biological activity. As with many investigational drugs, the pharmacokinetics, potential side effects, and interactions with other medications are important considerations in its therapeutic use. Overall, Rigosertib represents a promising avenue in targeted cancer therapy, with ongoing research aimed at optimizing its application in clinical settings.

Formula: C₂₁H₂₅NO₈S

InChI: InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+

InChI key: InChIKey=OWBFCJROIKNMGD-BQYQJAHWSA-N

SMILES: C(=C/S(CC1=CC(NCC(O)=O)=C(OC)C=C1)(=O)=O)\C2=C(OC)C=C(OC)C=C2OC

Synonyms:

• ON 01910
• 3: PN: WO2006074149 PAGE: 45 claimed sequence
• Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-
• N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine
• (E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone
• Rigosertib(acid)
• Rigosertib
• rigosertib(PI3K/Plk1 inhibitor)ORPHAN DRUG
• (E)-2-((2-Methoxy-5-(((2,4,6-triMethoxystyryl)sulfonyl)Methyl)phenyl)aMino)acetic acid
• CS-1407
• (2-METHOXY-5-[2-(2,4,6-TRIMETHOXY-PHENYL)-ETHENESULFONYLMETHYL]-PHENYLAMINO)-ACETIC ACID, SODIUM SALT

N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine

CAS: 592542-59-1

Formula: C₂₁H₂₅NO₈S

Purity: 98%

Color and Shape: Solid

Molecular weight: 451.4901

Ref: IN-DA00396Z

(E)-2-((2-Methoxy-5-(((2,4,6-Trimethoxystyryl)Sulfonyl)Methyl)Phenyl)Amino)Acetic Acid

CAS: 592542-59-1

(E)-2-((2-Methoxy-5-(((2,4,6-Trimethoxystyryl)Sulfonyl)Methyl)Phenyl)Amino)Acetic Acid

Purity: 98%

Molecular weight: 451.49g/mol

Ref: 54-OR1023328

Rigosertib

CAS: 592542-59-1

Rigosertib

Purity: ≥95%

Molecular weight: 451.49g/mol

Ref: 54-BUP16324

Rigosertib

CAS: 592542-59-1

Rigosertib, a multi-kinase inhibitor targeting PLK1 (IC50: 9 nM), induces apoptosis and G2/M arrest by disrupting PI3K/Akt.

Formula: C₂₁H₂₅NO₈S

Purity: 99.53%

Color and Shape: Solid

Molecular weight: 451.49

Ref: TM-T16750

Rigosertib-d6

Controlled Product

CAS: 592542-59-1

Formula: C₂₁D₆H₁₉NO₈S

Color and Shape: Neat

Molecular weight: 457.527

Ref: TR-R590714

Rigosertib

Controlled Product

CAS: 592542-59-1

Formula: C₂₁H₂₅NO₈S

Color and Shape: Neat

Molecular weight: 451.49

Ref: TR-R590713

Rigosertib-d6

CAS: 592542-59-1

Rigosertib is a small molecule that inhibits the activity of DNA methyltransferases. Rigosertib has been shown to have synergistic effects with other drugs, including anti-inflammatory agents, and is being studied as a potential treatment for cancer. Rigosertib has minimal toxicity in mice, with no signs of weight loss or hair loss at doses up to 5000 mg/kg, or death at 10,000 mg/kg. In a model system, rigosertib inhibited the growth of leukemia cells without affecting normal cells. Rigosertib may be useful for treating cancers such as breast cancer and prostate cancer because it blocks the tumor's ability to grow by inhibiting cell division.

Formula: C₂₁H₁₉D₆NO₈S

Purity: Min. 95%

Molecular weight: 457.53 g/mol

Ref: 3D-SYA54259